AstraZeneca's Breztri Shows Positive Results in Phase III Asthma Trials
Mar 20, 2026
AstraZeneca announced positive Phase III trial results for Breztri Aerosphere in uncontrolled asthma patients, showing statistically significant improvements over dual-combination therapies. Deutsche Bank maintained a Sell rating with a £115 price target.